Corrigendum to “The long-term safety and efficacy of vestronidase alfa, rhGUS enzyme replacement therapy, in subjects with mucopolysaccharidosis VII” [Mol Genet Metab 2020 Mar;129(3):219–227] (Molecular Genetics and Metabolism (2020) 129(3) (219–227), (S1096719219307851), (10.1016/j.ymgme.2020.01.003))

Raymond Y. Wang; José Francisco da Silva Franco; Jaime López-Valdez; Esmeralda Martins; Vernon Reid Sutton; Chester B. Whitley; Lin Zhang; Tricia Cimms; Deborah Marsden; Agnieszka Jurecka; Paul Harmatz

doi:10.1016/j.ymgme.2020.08.001

Corrigendum to “The long-term safety and efficacy of vestronidase alfa, rhGUS enzyme replacement therapy, in subjects with mucopolysaccharidosis VII” [Mol Genet Metab 2020 Mar;129(3):219–227] (Molecular Genetics and Metabolism (2020) 129(3) (219–227), (S1096719219307851), (10.1016/j.ymgme.2020.01.003))

Raymond Y. Wang, José Francisco da Silva Franco, Jaime López-Valdez, Esmeralda Martins, Vernon Reid Sutton, Chester B. Whitley, Lin Zhang, Tricia Cimms, Deborah Marsden, Agnieszka Jurecka, Paul Harmatz

Pediatrics - Genetics and Metabolism

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

We would like to correct the clinicaltrials.gov study registration number mentioned in the manuscript in several areas: In the abstract, the NCT number mentioned and linked (NCT02377921) is incorrect. The sentence that reads “… completed a Phase 3, randomized, placebo-controlled, blind-start, single crossover study (UX003-CL301; NCT02377921) …” should instead read, “… completed a Phase 3, randomized, placebo-controlled, blind-start, single crossover study (UX003-CL301; NCT02230566) … The link to the corrected NCT number should point to: https://clinicaltrials.gov/ct2/show/NCT02230566 The authors would like to apologize for any inconvenience caused. DOI of original article: doi: https://doi.org/10.1016/j.ymgme.2020.01.003

Original language	English (US)
Pages (from-to)	285
Number of pages	1
Journal	Molecular Genetics and Metabolism
Volume	131
Issue number	1-2
DOIs	https://doi.org/10.1016/j.ymgme.2020.08.001
State	Published - Sep 1 2020

Bibliographical note

Publisher Copyright:
© 2020 The Author(s)

Access

10.1016/j.ymgme.2020.08.001

OpenUrl availability

Full text

Fingerprint

Dive into the research topics of 'Corrigendum to “The long-term safety and efficacy of vestronidase alfa, rhGUS enzyme replacement therapy, in subjects with mucopolysaccharidosis VII” [Mol Genet Metab 2020 Mar;129(3):219–227] (Molecular Genetics and Metabolism (2020) 129(3) (219–227), (S1096719219307851), (10.1016/j.ymgme.2020.01.003))'. Together they form a unique fingerprint.

Cite this

Wang, R. Y., da Silva Franco, J. F., López-Valdez, J., Martins, E., Sutton, V. R., Whitley, C. B., Zhang, L., Cimms, T., Marsden, D., Jurecka, A., & Harmatz, P. (2020). Corrigendum to “The long-term safety and efficacy of vestronidase alfa, rhGUS enzyme replacement therapy, in subjects with mucopolysaccharidosis VII” [Mol Genet Metab 2020 Mar;129(3):219–227] (Molecular Genetics and Metabolism (2020) 129(3) (219–227), (S1096719219307851), (10.1016/j.ymgme.2020.01.003)). Molecular Genetics and Metabolism, 131(1-2), 285. https://doi.org/10.1016/j.ymgme.2020.08.001

Corrigendum to “The long-term safety and efficacy of vestronidase alfa, rhGUS enzyme replacement therapy, in subjects with mucopolysaccharidosis VII” [Mol Genet Metab 2020 Mar;129(3):219–227] (Molecular Genetics and Metabolism (2020) 129(3) (219–227), (S1096719219307851), (10.1016/j.ymgme.2020.01.003)). / Wang, Raymond Y.; da Silva Franco, José Francisco; López-Valdez, Jaime et al.
In: Molecular Genetics and Metabolism, Vol. 131, No. 1-2, 01.09.2020, p. 285.

Research output: Contribution to journal › Comment/debate › peer-review

Wang, RY, da Silva Franco, JF, López-Valdez, J, Martins, E, Sutton, VR, Whitley, CB, Zhang, L, Cimms, T, Marsden, D, Jurecka, A & Harmatz, P 2020, 'Corrigendum to “The long-term safety and efficacy of vestronidase alfa, rhGUS enzyme replacement therapy, in subjects with mucopolysaccharidosis VII” [Mol Genet Metab 2020 Mar;129(3):219–227] (Molecular Genetics and Metabolism (2020) 129(3) (219–227), (S1096719219307851), (10.1016/j.ymgme.2020.01.003))', Molecular Genetics and Metabolism, vol. 131, no. 1-2, pp. 285. https://doi.org/10.1016/j.ymgme.2020.08.001

Wang RY, da Silva Franco JF, López-Valdez J, Martins E, Sutton VR, Whitley CB et al. Corrigendum to “The long-term safety and efficacy of vestronidase alfa, rhGUS enzyme replacement therapy, in subjects with mucopolysaccharidosis VII” [Mol Genet Metab 2020 Mar;129(3):219–227] (Molecular Genetics and Metabolism (2020) 129(3) (219–227), (S1096719219307851), (10.1016/j.ymgme.2020.01.003)). Molecular Genetics and Metabolism. 2020 Sep 1;131(1-2):285. doi: 10.1016/j.ymgme.2020.08.001

Wang, Raymond Y. ; da Silva Franco, José Francisco ; López-Valdez, Jaime et al. / Corrigendum to “The long-term safety and efficacy of vestronidase alfa, rhGUS enzyme replacement therapy, in subjects with mucopolysaccharidosis VII” [Mol Genet Metab 2020 Mar;129(3):219–227] (Molecular Genetics and Metabolism (2020) 129(3) (219–227), (S1096719219307851), (10.1016/j.ymgme.2020.01.003)). In: Molecular Genetics and Metabolism. 2020 ; Vol. 131, No. 1-2. pp. 285.

@article{34ddac8ca0bd4e4ab84cb4c848ccb5c5,

title = "Corrigendum to “The long-term safety and efficacy of vestronidase alfa, rhGUS enzyme replacement therapy, in subjects with mucopolysaccharidosis VII” [Mol Genet Metab 2020 Mar;129(3):219–227] (Molecular Genetics and Metabolism (2020) 129(3) (219–227), (S1096719219307851), (10.1016/j.ymgme.2020.01.003))",

abstract = "We would like to correct the clinicaltrials.gov study registration number mentioned in the manuscript in several areas: In the abstract, the NCT number mentioned and linked (NCT02377921) is incorrect. The sentence that reads “… completed a Phase 3, randomized, placebo-controlled, blind-start, single crossover study (UX003-CL301; NCT02377921) …” should instead read, “… completed a Phase 3, randomized, placebo-controlled, blind-start, single crossover study (UX003-CL301; NCT02230566) … The link to the corrected NCT number should point to: https://clinicaltrials.gov/ct2/show/NCT02230566 The authors would like to apologize for any inconvenience caused. DOI of original article: doi: https://doi.org/10.1016/j.ymgme.2020.01.003",

author = "Wang, {Raymond Y.} and {da Silva Franco}, {Jos{\'e} Francisco} and Jaime L{\'o}pez-Valdez and Esmeralda Martins and Sutton, {Vernon Reid} and Whitley, {Chester B.} and Lin Zhang and Tricia Cimms and Deborah Marsden and Agnieszka Jurecka and Paul Harmatz",

note = "Publisher Copyright: {\textcopyright} 2020 The Author(s)",

year = "2020",

month = sep,

day = "1",

doi = "10.1016/j.ymgme.2020.08.001",

language = "English (US)",

volume = "131",

pages = "285",

journal = "Molecular Genetics and Metabolism",

issn = "1096-7192",

publisher = "Academic Press Inc.",

number = "1-2",

}

TY - JOUR

T1 - Corrigendum to “The long-term safety and efficacy of vestronidase alfa, rhGUS enzyme replacement therapy, in subjects with mucopolysaccharidosis VII” [Mol Genet Metab 2020 Mar;129(3):219–227] (Molecular Genetics and Metabolism (2020) 129(3) (219–227), (S1096719219307851), (10.1016/j.ymgme.2020.01.003))

AU - Wang, Raymond Y.

AU - da Silva Franco, José Francisco

AU - López-Valdez, Jaime

AU - Martins, Esmeralda

AU - Sutton, Vernon Reid

AU - Whitley, Chester B.

AU - Zhang, Lin

AU - Cimms, Tricia

AU - Marsden, Deborah

AU - Jurecka, Agnieszka

AU - Harmatz, Paul

PY - 2020/9/1

Y1 - 2020/9/1

N2 - We would like to correct the clinicaltrials.gov study registration number mentioned in the manuscript in several areas: In the abstract, the NCT number mentioned and linked (NCT02377921) is incorrect. The sentence that reads “… completed a Phase 3, randomized, placebo-controlled, blind-start, single crossover study (UX003-CL301; NCT02377921) …” should instead read, “… completed a Phase 3, randomized, placebo-controlled, blind-start, single crossover study (UX003-CL301; NCT02230566) … The link to the corrected NCT number should point to: https://clinicaltrials.gov/ct2/show/NCT02230566 The authors would like to apologize for any inconvenience caused. DOI of original article: doi: https://doi.org/10.1016/j.ymgme.2020.01.003

AB - We would like to correct the clinicaltrials.gov study registration number mentioned in the manuscript in several areas: In the abstract, the NCT number mentioned and linked (NCT02377921) is incorrect. The sentence that reads “… completed a Phase 3, randomized, placebo-controlled, blind-start, single crossover study (UX003-CL301; NCT02377921) …” should instead read, “… completed a Phase 3, randomized, placebo-controlled, blind-start, single crossover study (UX003-CL301; NCT02230566) … The link to the corrected NCT number should point to: https://clinicaltrials.gov/ct2/show/NCT02230566 The authors would like to apologize for any inconvenience caused. DOI of original article: doi: https://doi.org/10.1016/j.ymgme.2020.01.003

UR - http://www.scopus.com/inward/record.url?scp=85089738882&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85089738882&partnerID=8YFLogxK

U2 - 10.1016/j.ymgme.2020.08.001

DO - 10.1016/j.ymgme.2020.08.001

M3 - Comment/debate

C2 - 32843286

AN - SCOPUS:85089738882

SN - 1096-7192

VL - 131

SP - 285

JO - Molecular Genetics and Metabolism

JF - Molecular Genetics and Metabolism

IS - 1-2

ER -